Eli Lilly presented detailed trial data for its experimental obesity drug, retatrutide, at the American Diabetes Association (ADA) conference. The data indicates retatrutide likely offers the highest weight loss among all existing and pipeline treatments, setting a new competitive benchmark. Analysts noted that rival drugs from Roche and Novo Nordisk do not match the profile of Lilly’s next-generation assets.
Eli Lilly shares rose 1.6% on the first trading day following the presentations. Shares of competitor Novo Nordisk fell 4.2% as other companies in the space also declined. This pipeline strength in the GLP-1 category remains a primary driver of investor sentiment for Lilly and the broader pharmaceutical sector.